Comparative Pharmacology
Head-to-head clinical analysis: HYDROXYUREA versus SIKLOS.
Peer-Reviewed Evidence
Head-to-head clinical analysis: HYDROXYUREA versus SIKLOS.
HYDROXYUREA vs SIKLOS
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Inhibits ribonucleotide reductase, leading to decreased DNA synthesis and cell cycle arrest in S phase; also increases fetal hemoglobin production by inducing nitric oxide and altering erythroid progenitor signaling.
Hydroxyurea inhibits ribonucleotide reductase, reducing the synthesis of deoxyribonucleotides and thereby decreasing DNA synthesis. In sickle cell disease, it increases fetal hemoglobin (HbF) levels, which inhibits sickling of red blood cells.
Oral: 15-20 mg/kg once daily (rounded to nearest 500 mg) for myeloproliferative disorders (e.g., essential thrombocythemia); 80 mg/kg every 3 days (as 35 mg/kg single dose) for sickle cell disease.
100–200 mg/kg/day orally in two divided doses, not to exceed 200 mg/kg/day.
None Documented
None Documented
Clinical Note
moderateHydroxyurea + Digoxin
"Hydroxyurea may decrease the cardiotoxic activities of Digoxin."
Clinical Note
moderateHydroxyurea + Digitoxin
"Hydroxyurea may decrease the cardiotoxic activities of Digitoxin."
Clinical Note
moderateHydroxyurea + Deslanoside
"Hydroxyurea may decrease the cardiotoxic activities of Deslanoside."
Clinical Note
moderateHydroxyurea + Acetyldigitoxin
"Hydroxyurea may decrease the cardiotoxic activities of Acetyldigitoxin."
Terminal half-life: 3.5–4.5 hours; clinical context: hematologic effects persist for 24-48 hours due to irreversible inhibition of ribonucleotide reductase.
Terminal elimination half-life is 2-5 hours in adults; shorter in children (1-2 hours). Clinical context: requires thrice-daily dosing to maintain therapeutic concentrations; longer half-life in hepatic impairment (up to 10 hours).
Renal: approximately 80% (30-60% unchanged; remainder as metabolites). Fecal: <10%.
Primarily hepatic metabolism via CYP3A4; renal excretion of metabolites accounts for approximately 70-80% of the dose, with <1% excreted unchanged in urine. Fecal excretion is minor (<5%).
Category A/B
Category C
Antimetabolite
Antimetabolite